AstraZeneca Plc (AZN)

53.85
0.02 0.04
NYSE : Health Technology
Prev Close 53.87
Open 54.34
Day Low/High 53.74 / 54.54
52 Wk Low/High 36.15 / 57.44
Volume 6.08M
Avg Volume 5.27M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 142.09B
EPS 0.50
P/E Ratio 24.16
Div & Yield 1.37 (2.49%)

Latest News

Tight Trading Ranges, China News, Amazon 'Prime Day'

Tight Trading Ranges, China News, Amazon 'Prime Day'

A look at those stocks likely to lead in the short- and long-term, the headlines out of China and Hong Kong, and the import of fiscal stimulus.

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Earnings in Full Swing, Workplace Evolution, Fed Day

Earnings in Full Swing, Workplace Evolution, Fed Day

There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.

AstraZeneca Could Pause a While Before Challenging the Old Highs

AstraZeneca Could Pause a While Before Challenging the Old Highs

Let's review the charts and indicators.

3 Strong Long-Term Buys for Uncertain Times

3 Strong Long-Term Buys for Uncertain Times

These pharmaceutical names have what it takes amid the current crisis and for the long run.

Amazon vs. Microsoft, Assessing the Virus, Sticking Up for Judy Shelton

Amazon vs. Microsoft, Assessing the Virus, Sticking Up for Judy Shelton

Fed repo policy changes confirm that external issues are having only a small impact on U.S. economic performance.

Why AbbVie Looks Like a Bargain at These Levels

Why AbbVie Looks Like a Bargain at These Levels

Nobody in AbbVie right now is in it for the past performance.

Genprex: The Bad and the Good of Capital Raises

Genprex: The Bad and the Good of Capital Raises

For those who love a roll of the dice, GNPX may be worth a closer look.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

High Flyers and Low Flyers

Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...

Now at the Plate, Your Pinch Hitter, Bret Jensen

I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?

The New Small Biotechs Heating Up the Medical Cannabis Space

The New Small Biotechs Heating Up the Medical Cannabis Space

These companies are working to plant their flag in a new landscape.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

Novice Trade: EWU United Kingdom ETF

Novice Trade: EWU United Kingdom ETF

This at-the-money, long put shooter is a high risk trade, so use discretionary capital.

Novice Trade: EWU ETF

Novice Trade: EWU ETF

This portfolio cannot be trusted to be diversified enough.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.